Publications

5677 Results

Phase II studies of hydroxyurea (NSC-32065) in adults: Multiple myeloma and lymphoma.

Authors
P Davis
Journal / Conference
Cancer Chemotherapy Reports 40:51-52
Year
1964
Research Committee(s)
Lymphoma and Myeloma

Erythrokinetic abnormalities with administration of hydroxyurea (NSC-32065).

Authors
CP Alfrey Jr;RJ Karjalan;SC Dale;EP Frenkel;M Lane
Journal / Conference
Cancer Chemotherapy Reports 40:27-30
Year
1964

Megaloblastic erythropoiesis induced by hydroxyurea.

Authors
DE Bergsagel;EP Frenkel;CP Alfrey Jr;WG Thurman
Journal / Conference
Cancer Chemotherapy Reports 40:15-17
Year
1964

Pediatric clinical trials with hydroxyurea (NSC-30265).

Authors
DJ Fernbach
Journal / Conference
Cancer Chemotherapy Reports 40:37-38
Year
1964

Studies on a metabolic defect induced by hydroxyurea (NSC-30265).

Authors
EP Frenkel;WN Skinner;JD Smiley
Journal / Conference
Cancer Chemotherapy Reports 40:19-22
Year
1964

Hydroxyurea (NSC-32065): Results of a Phase I study.

Authors
KM Griffith
Journal / Conference
Cancer Chemotherapy Reports 40:33-36
Year
1964

Vincristine (NSC-67574) in uncommon malignant disease in children.

Authors
TB Haddy;DJ Fernbach;WL Watkins;MP Sullivan;J Windmiller
Journal / Conference
Cancer Chemotherapy Reports 41: 41-45
Year
1964

Cyclophosphamide (NSC-26271) in uncommon malignant neoplasms in children.

Authors
TM Holcomb;ME Haggard;J Windmiller
Journal / Conference
Cancer Chemotherapy Reports 36:73-75
Year
1964

Phase II studies of hydroxyurea (NSC-32065) in adults: Clinical evaluation.

Authors
IH Krakoff;H Savel;ML Murphy
Journal / Conference
Cancer Chemotherapy Reports 40:53-55
Year
1964

Preliminary survey of hydroxyurea (NSC-32065) as a teratogen.

Authors
ML Murphy;S Chaube
Journal / Conference
Cancer Chemotherapy Reports 40:1-7
Year
1964